Key result
GPIIb/IIIa inhibitors are effective anti-platelet agents in cardiovascular medicine, though oral antagonists have failed and there remains a need for orally active drugs with lower bleeding risk.
This review summarizes the current knowledge on GPIIb/IIIa inhibitors, their clinical utility in cardiovascular medicine, and the ongoing need for safer, orally available alternatives.
Answers are grounded in this paper and cite their sources.
Underscores unmet need for safer oral GPIIb/IIIa inhibitors; leaves open optimal designs for future agents.
The platelet integrin GPIIb/IIIa plays an essential role in thrombus formation through interactions with adhesive ligands and has emerged as a primary target for the development of anti-thrombotic agents. Receptor activation is under strict control, with activators, inhibitors, and signalling mechanisms controlling its conformation. Structural biology research has produced high-resolution images defining the ligand binding site at the atomic level. Successful blockade of this ligand binding has validated GPIIb/IIIa as a therapeutic target in cardiovascular medicine. GPIIb/IIIa inhibitors were the first rationally designed anti-platelet agents and have been used effectively in a wide variety of clinical scenarios including unstable angina, myocardial infarction, and high risk percutaneous coronary interventions with and without intracoronary stenting. Three inhibitors (abciximab, eptifibatide, and tirofiban) are currently licensed for human use. Surprisingly, oral GPIIb/IIIa antagonists have not been successful and there is an unmet need for effective anti-GPIIb/IIIa drugs that cause less bleeding problems and that can be orally applied. Here we review our current knowledge about GPIIb/IIIa structure, signalling pathways and receptor function, the benefits and limitations of current GPIIb/IIIa blockers and we take a look forward how the lessons learned from the mixture of success and failure of GPIIb/IIIa blocker development can be transformed in new and better GPIIb/IIIa blockers.
No takes yet. Share an insight, caveat, or question.
Hagemeyer et al. (2010) conducted a review in Cardiovascular disease (unstable angina, myocardial infarction, high risk percutaneous coronary interventions). GPIIb/IIIa inhibitors was evaluated. GPIIb/IIIa inhibitors are effective anti-platelet agents in cardiovascular medicine, though oral antagonists have failed and there remains a need for orally active drugs with lower bleeding risk.
Synapse has enriched 10 related papers. Consider them for comparative context: